ORIGINAL ARTICLE

Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn’s disease

Peng Chen¹,†, Shanshan Huang¹,†, Qiao Yu², Kang Chao³, Ying Wang¹, Gaoshi Zhou¹, Xiaojun Zhuang¹, Zhirong Zeng¹, Minhu Chen¹ and Shenghong Zhang¹,*

¹Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China, ²Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P. R. China; ³Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China

*Corresponding author. Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, P. R. China. Tel: +86-20-87755766; Email: shenghongzhang@163.com or zhshh3@mail.sysu.edu.cn
†These authors contributed equally to this work.

Abstract

Background: Crohn’s disease (CD) has a tendency for recurrence and requires adequate monitoring and personalized treatment. Since endoscopy is considerably invasive, serum biomarkers are required as alternatives for CD monitoring. Toward this, exosomal microRNAs (miRNAs) may serve as promising candidates. In this study, we aimed to assess the role of serum exosomal microRNA-144-3p (miR-144-3p) as a biomarker for CD monitoring.

Methods: We prospectively recruited 154 patients without a history of surgery (Cohort 1) and 75 patients who were to undergo intestinal resection (Cohort 2). Serum samples were collected from Cohort 1 before colonoscopy and from Cohort 2 before surgery and during post-operative colonoscopic examination. The serum levels of exosomal miR-144-3p were measured using quantitative reverse-transcription polymerase chain reaction (PCR). Correlations between relative exosomal miR-144-3p levels, disease activity, and disease behavior were analysed. The area under the receiver-operating characteristic curve (AUC) was used to assess the predictive value of exosomal miR-144-3p regarding mucosal activity and post-operative recurrence.

Results: A 3.33-fold increase in serum exosomal miR-144-3p levels was recorded in patients with CD compared with those in healthy controls (P < 0.001). The exosomal miR-144-3p levels were positively correlated with the simple endoscopic score of CD (r = 0.547, P < 0.001) as well as the Rutgeerts score (r = 0.478, P < 0.001). Elevated exosomal miR-144-3p levels were correlated with the penetrating disease with high specificity (100% [95% confidence interval, 95.1%–100%]). The accuracy of exosomal miR-144-3p for identifying post-operative recurrence was higher than that of C-reactive protein (CRP) (AUC, 0.775 vs 0.639; P < 0.001).

Conclusions: Serum exosomal miR-144-3p is a reliable biomarker of mucosal inflammation and penetrating CD. It may identify endoscopic CD recurrence after intestinal resection with higher accuracy than CRP testing.

Key words: Crohn’s disease; microRNA-144-3p; serum biomarker; exosome

Submitted: 22 June 2021; Revised: 9 September 2021; Accepted: 10 October 2021
© The Author(s) 2021. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Crohn’s disease (CD), a subtype of inflammatory bowel disease (IBD), is a chronic inflammatory disease of the gastrointestinal tract, which arises from complex interactions among genetic susceptibility, environmental factors, microbial dysbiosis, and immune responses [1]. Effective control of inflammation is critical to prevent disease progression and long-term complications [2]. Moreover, early identification of disease flare-up and complications in patients with mild symptoms is essential to achieve better treatment responses [3]. The treat-to-target concept (based on mucosal healing) is commonly accepted. Adequate disease monitoring is the key to timely treatment adjustments [4]. Moreover, nearly 70% of patients with CD require intestinal surgery at least once in their lifetime [5]. Therefore, it is important to predict post-operative recurrence and make timely decisions. Ileocolonoscopy is a standard criterion for evaluating and monitoring mucosal inflammation; however, this method is costly and associated with risks and discomfort, especially in post-surgical resection patients [6, 7]. C-reactive protein (CRP), the erythrocyte sedimentation rate (ESR), and fecal calprotectin are the most common minimally or non-invasive biomarkers of inflammation used in the clinical diagnosis of CD. However, these markers cannot accurately predict mucosal active disease due to their low negative predictive value (NPV) [8]. CRP production varies between patients owing to genetic heterogeneity, and normal CRP levels can be observed under inflammatory conditions [3]. Fecal-calprotectin levels observed may be biased due to differences regarding detection platforms, collection techniques, stool characteristics, and other factors, thus lacking technical and clinical reliability for monitoring the endoscopic activity of CD [9]. Therefore, reliable non-invasive methods to monitor CD are urgently required.

Exosomes are nanovesicles with a diameter of 40–160 nm, which are generated in the endosomal system by different cell types. Importantly, exosomes mediate gene expression and cellular function by conveying signals and molecules to distal cells. Exosomes carry specific functional proteins, metabolites, and nucleic acids, including DNA and various types of RNAs [10]; prior research has shown that ~80% of exosomal RNAs (exoRNAs) are microRNAs (miRNAs) [11]. miRNAs are short (~18–24 nucleotides) non-coding RNAs, which regulate gene expression through mRNA degradation and the inhibition of translation. Dysregulation of certain miRNAs has been causally associated with several autoimmune and neoplastic diseases [12, 13]. Exosomal miRNAs may promote inflammatory responses by modulating the functions of immune cells and the NF-κB signaling pathway in patients with IBD [14, 15]. Furthermore, several studies have proposed the clinical significance of miRNAs as non-invasive biomarkers for various types of cancers, inflammatory diseases, and age-related diseases [16–20]. To date, the use of circulating miRNAs as IBD biomarkers is mostly limited to circulating total cell-free miRNAs [21–25]. Circulating cell-free miRNAs include exosomal miRNAs actively secreted by cells, as well as miRNAs bound to protein complexes that are passively released by apoptotic and necrotic cells. Therefore, exosomal miRNAs may be accurate markers of pathological changes and may have higher disease specificity than cell-free miRNAs [26, 27]. Moreover, exosomal miRNAs are remarkably stable against degradation during long-term storage, as they are protected by the lipoprotein complex structure of the exosome. Conversely, circulating miRNAs not encapsulated in vesicles can easily be degraded by proteinase K and ribonucleases (RNases), limiting the accuracy and reproducibility of serum miRNAs as biomarkers [28].

The predictive value of serum exosomal miRNAs in patients with CD has not been studied to date. Therefore, we assessed whether serum exosomal miRNAs could be used as non-invasive biomarkers for IBD monitoring. miR-144-3p was selected from our exosomal miRNA microarray data of serum samples and its predictive value for endoscopic activity was explored in a prospective study with two independent cohorts. Correlations between exosomal miR-144-3p levels and the CD-activity index (CDAI), the simple endoscopic score for CD (SES-CD), and the Rutgeerts score were evaluated. Our findings suggest that the expression of circulating exosomal miR-144-3p may be a reliable biomarker to detect endoscopically active disease and early post-operative recurrence in patients with CD.

Patients and methods

Study subjects

Between May 2017 and May 2019, 229 patients with CD, prospectively admitted in the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China), the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China), and the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China), were recruited. One hundred age- and sex-matched healthy individuals were also recruited and underwent colonoscopy for routine health check-ups (including those who had a family history of polyposis and colorectal cancer); none of them had any digestive symptoms and endoscopically abnormal manifestations. Patients with CD were diagnosed based on clinical presentation, ileocolonoscopy, histology, radiology, and laboratory tests, with complete clinical data and regular follow-up examinations [29]. Patients with concurrent autoimmune diseases, recent infections, malignant diseases, and pregnancy were excluded. In addition, demographic data, disease duration, and previous treatments of all patients were recorded. This study was approved by the research ethics committees of the First Affiliated Hospital of Sun Yat-sen University ([2018]52 and [2021]356), the Second Affiliated Hospital of Zhejiang University School of Medicine (2018–132), and the Sixth Affiliated Hospital of Sun Yat-sen University (2016ZLYEC-053). Written informed consent was obtained from all participants.

Study design

We collected serum samples from three patients with active CD and three healthy volunteers, and performed exosome miRNA microarray analysis (Supplementary Figure 1). Significantly differentially expressed miRNAs (fold change > 2; P < 0.001) were selected and compared with previous miRNA microarray data of the colon tissue [24]; miR-144-3p was highly upregulated in the serum and colon tissue of patients with CD, which was the single congruent result of the two miRNA microarrays. Previous studies have also reported overexpression of miR-144 in the colonic mucosa of CD patients [30]; therefore, we assessed the value of serum exosomal miR-144-3p for CD monitoring. Two independent cohorts were enrolled: Cohort 1 included 154 CD patients without a history of gastrointestinal surgery and 100 healthy controls; Cohort 2 included 75 CD patients who underwent intestinal resection. Patients in Cohort 1 underwent
Ileocolonoscopy at their first visit, when symptoms flared up, or during regular reexamination. Patients in Cohort 2 were followed up for 18 months; they underwent ileocolonoscopy after surgery when suffering from the digestive symptoms of disease recurrence or periodic reexamination within 18 months. The end point was post-operative endoscopic recurrence. In Cohort 1, the correlation between the serum exosomal miR-144-3p levels and the disease activity (CDAI and SES-CD) was explored, and the correlation between the latter and the serum total cell-free miR-144-3p was evaluated; correlations of serum exosomal miR-144-3p and medication, disease behavior, and disease location were also evaluated. In Cohort 2, correlations between serum exosomal miR-144-3p levels and endoscopic recurrence (Rutgeerts score ≥12) were explored. The predictive value of miR-144-3p levels for endoscopic recurrence was compared with that of CRP and ESR.

**Disease-activity assessment and blood-sample collection**

Endoscopic activity was evaluated according to SES-CD or Rutgeerts scores for CD by experienced physicians who were blinded to clinical information and test results. An SES-CD score of ≥3 was considered to indicate endoscopically active CD [31]. Post-operative endoscopic recurrence refers to the reappearance of mucosal lesions after surgery, defined by a Rutgeerts score of ≥12 (moderate to severe lesions) [32]. Blood samples were collected for exoRNA extraction and laboratory tests, including those for the inflammatory markers CRP and ESR. In Cohort 1, blood samples were collected within 1 week prior to ileocolonoscopy. In Cohort 2, blood samples were collected from patients who underwent intestinal resection before surgery within 1 week of the procedure; additionally, blood samples were also collected within 1 week prior to post-operative colonoscopy. Laboratory parameters CRP and ESR were recorded. Evaluation of clinical disease activity and collection of blood samples were performed simultaneously. Clinical disease activity was evaluated prospectively using the CDAI. A CDAI score of ≥150 points was considered as clinically active disease [29]. We categorized disease location and phenotype using the Montreal classification [33].

**Exosomal RNA extraction and quantitative real-time polymerase chain reaction (RT-qPCR)**

Blood samples were drawn in blood-collection tubes with a clot activator and were processed within 1 h. Samples were centrifuged at 1,900 × g and 4 °C for 10 mins, and further passed through a 0.8-μm filter to remove cellular material and retain exosomes. Serum samples were frozen in aliquots at −80 °C prior to RNA extraction. ExoRNA was extracted using an exoRNeasy Serum/Plasma Maxi Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions, showing high purity and recovery yield of exoRNA without isolation of serum exosomes [34, 35]. Serum total cell-free miRNAs were isolated using a miRNeasy Serum/Plasma Kit (Qiagen). Mature miRNAs were reverse-transcribed to cDNA following polyadenylation (miScript II RT Kit, Qiagen). RT-qPCR was carried out on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) using a miScript SYBR Green PCR Kit (Qiagen). U6sn was used as an internal control to normalize the miRNA expression [26].

**Statistical analyses**

IBM SPSS Statistics 20 (IBM, Armonk, NY, USA) was used for data analyses. A Durbin–Watson test was used to analyse data distribution, the \( z^2 \) method was used for relative miR-144-3p quantification, and a Kruskal–Wallis test was used for comparisons among multiple groups. In addition, a Mann–Whitney U test was used for pairwise comparisons of non-normally distributed variables. Correlations between two variables were evaluated using the Spearman rank correlation coefficient (\( r \)) for nonparametric correlations. Receiver-operating characteristic (ROC) curves were used to estimate the accuracy of disease-behavior, mucosal-activity, and endoscopic-recurrence assessments. A chi-square test was applied to compare sensitivity and specificity, and the DeLong’s method was used to compare the areas under ROC curves (AUC) (MedCalc version 19.6.1, MedCalc Software bv, Ostend, Belgium). The tests were two-tailed and statistical significance is reported at \( P < 0.05 \). Bonferroni corrections were used to adjust significance levels after multiple testing [36].

**Results**

**Elevated serum exosomal miR-144-3p in patients with CD**

Baseline demographics of CD patients and healthy controls in Cohort 1 are shown in Table 1; no significant differences in demographic characteristics, including age and sex, were observed between the two groups. A Kruskal–Wallis test showed no statistical difference in the total serum miR-144-3p and exosomal miR-144-3p levels among patients who took different medications (\( P = 0.861 \) and \( P = 0.710 \), respectively). Disease duration was not correlated with total serum miR-144-3p and exosomal miR-144-3p levels (\( r = -0.122, P = 0.132 \) and \( r = 0.018, P = 0.829 \), respectively). Total serum miR-144-3p and exosomal miR-144-3p levels were significantly higher in CD patients than in healthy controls (fold change \( \text{CD/HC} \) 2.24 and 3.33, respectively; \( P < 0.001 \) each). Total serum miR-144-3p levels were not significantly correlated with serum-exosome-derived miR-144-3p levels. Serum exosomal miR-144-3p levels were 3.94- and 2.12-fold higher in patients with active CD than those in healthy controls and patients with endoscopic remission, respectively (\( P < 0.001 \); Figure 1), while no significant difference was observed in the serum total miR-144-3p levels between mucosal active disease and quiescent disease (\( P = 0.116 \)).

**Predictive value of serum exosomal miR-144-3p for endoscopically active disease**

Circulating total miR-144-3p was not significantly correlated with CDAI (\( r = -0.037, P = 0.669 \)) or SES-CD (\( r = 0.131, P = 0.091 \)) in CD patients; however, serum exosomal miR-144-3p levels were positively correlated with CDAI (\( r = 0.343, P < 0.001 \)) and SES-CD (\( r = 0.547, P < 0.001 \); Figure 2). Serum exosomal miR-144-3p levels were positively correlated with CRP (\( r = 0.332, P < 0.001 \)) and ESR (\( r = 0.289, P < 0.001 \); Table 2). ROC analysis showed that circulating exosomal miR-144-3p had a high diagnostic accuracy for endoscopically active disease in CD patients (AUC, 0.761; 95% confidence interval [CI], 0.685–0.826; \( P < 0.001 \); Figure 3). The cut-off value for mucosal lesions was 3.11, with 70.2% sensitivity (95% CI, 60.4%–78.8%), 82.0% specificity (95% CI, 68.6%–91.4%), 89.0% positive predictive value (PPV) (95% CI, 82.1%–95.9%), and 56.9% NPV (95% CI, 45.2%–68.6%).
Association of serum exosomal miR-144-3p levels and penetrating disease behavior

Due to the close relationship between serum exosomal miR-144-3p and disease activity, we evaluated the predictive value of the former for disease behavior and disease location in patients with mucosal active disease. The expression of serum exosomal miR-144-3p was significantly higher in patients showing penetrating disease behavior than in those showing inflammatory (P = 0.001) and stricturing disease behaviors (P = 0.005); no significant difference was observed between patients showing inflammatory and stricturing disease behaviors (Figure 4). Relative serum exosomal miR-144-3p levels of >8.92 were found to have 100% specificity (95% CI, 95.1%–100%) and 100% PPV (95% CI, 95.1%–100%) for the penetrating phenotype in patients with active CD with 33.3% sensitivity (95% CI, 17.3%–52.8%), 78.7% NPV (95% CI, 70.3%–87.2%), and an AUC of 0.719 (95% CI: 0.622–0.803). Serum exosomal miR-144-3p levels were not associated with the disease location (P = 0.078).

Accuracy of serum exosomal miR-144-3p levels for identifying endoscopic recurrence

Demographic characteristics of the 75 CD patients in Cohort 2 who underwent intestinal resection are shown in Table 3. At 18 months after surgery, all patients had undergone a colonoscopy and 45.3% experienced endoscopic recurrence. Serum exosomal miR-144-3p levels significantly decreased after intestinal resection (2.16-fold; P < 0.001); however, elevated expression of exosomal miR-144-3p was found in patients with endoscopic recurrence, with a fold change of 2.52 (endoscopic recurrence/remission; P < 0.001; Figure 5). Serum exosomal miR-144-3p levels were also positively correlated with the Rutgeerts score (r = 0.478; P < 0.001; Table 2). To identify patients with endoscopic recurrence, ROC analysis revealed that exosomal miR-144-3p had an AUC of 0.775 (95% CI, 0.664–0.864), which was significantly higher than that of the inflammatory marker CRP (0.639 [95% CI, 0.520–0.747]; P = 0.030) and ESR (0.591 [95% CI, 0.471–0.703]; P = 0.192; Figure 6). The optimal threshold was 2.73 at 58.8% sensitivity (95% CI, 40.7%–75.4%), 92.7% specificity (95% CI, 80.1%–98.5%), 87.0% PPV (95% CI, 72.1%–98.6%), and 73.1% NPV (95% CI, 60.6%–85.5%; Table 4).
In this study, we determined the clinical significance of serum exosomal miR-144-3p as a non-invasive biomarker in two independent cohorts of CD patients. We confirmed that exosomal miR-144-3p levels were significantly higher in patients with CD, particularly in patients with penetrating disease. Furthermore, serum exosomal miR-144-3p was strongly correlated with endoscopic activity and showed better performance than CRP in identifying endoscopic recurrence after intestinal resection.

CD is characterized by alternating periods of remission and relapse. Most patients with CD require intestinal surgery over the course of the disease. Therefore, adequate monitoring of recurrent inflammation with timely personalized treatment is essential to reduce the severity of the disease and the need for further surgery [3]. Various biomarkers have been tested to
evaluate disease activity to reduce repeated invasive examinations such as endoscopies. Prior research has indicated that circulating cell-free miRNAs are attractive biomarkers for various pathological conditions [13]. Serum total cell-free miRNAs include miRNAs derived from exosomes and miRNAs that bind to proteins; the latter are mainly released passively by apoptotic and necrotic cells. In contrast, exosomal miRNAs are specifically selected, encapsulated in vesicles, and actively secreted to mediate biological processes, and thus are more disease-specific for certain pathological conditions [11]. Moreover, exosomes containing miRNAs are remarkably stable and can thus be collected, transported, and stored conveniently, whereas other serum miRNAs are rapidly degraded by RNases. Notably, the ratio of exosomal serum miRNAs to total serum miRNAs varies substantially between individuals, and the total serum levels of a respective miRNA are not correlated with its levels in exosomes [28]. Therefore, exosomal miRNAs may be more reliable biomarkers.

Previous studies have shown that exosomal miRNAs derived from immune cells and colonic epithelial cells regulate immunity and intestinal barrier functions during IBD [15]. Recently, exosomal proteins annexin A1, PSMA7, and exosomal lncRNA NEAT1 have been reported to be correlated with disease severity; thus, they may serve as IBD diagnostic biomarkers [37–39]. However, few studies have evaluated the potential of exosomal miRNAs as non-invasive IBD biomarkers. In the current study, we selected miR-144-3p from the microarray data of serum and colon-tissue samples. We compared the expression of total serum miR-144-3p and serum exosomal miR-144-3p between CD patients and healthy controls. We found that serum levels of total miR-144-3p were not associated with exosomal miR-144-3p levels; both were considerably higher in CD patients than in healthy controls. However, while exosomal miR-144-3p in patients with active CD showed a fold change that was 2.12 higher than in patients with endoscopic remission (P < 0.001), no significant difference was observed in the total serum miR-144-3p levels between the active and quiescent diseases. Moreover, serum exosomal miR-144-3p was positively correlated with CDAI and SES-CD, whereas the serum total miR-144-3p did not correlate with disease severity. Thus, we concluded that serum exosomal miR-144-3p was more reliable for CD monitoring than total serum cell-free miR-144-3p.

Unlike disease location, which may remain unaltered during the disease course, the behavior of CD may change over time.

### Table 3. Demographic and clinical characteristics of 75 patients with CD in Cohort 2

| Characteristic                        | Value                   |
|---------------------------------------|-------------------------|
| Male, n (%)                           | 52 (69.3)               |
| Age, years, median (IQR)              | 31.0 (25.0–43.0)        |
| Disease duration, months, median (IQR)| 48.0 (36.0–111.6)       |
| Resection type, n (%)                 |                         |
| Ileocecal                             | 32 (42.7)               |
| Isolated ileal                        | 19 (25.3)               |
| Subtotal colectomy                    | 18 (24.0)               |
| Ileocecal and sigmoid                 | 4 (5.3)                 |
| Ileocecal and small bowel             | 2 (2.7)                 |
| Disease phenotype, n (%)              |                         |
| Inflammatory (B1)                     | 5 (6.7)                 |
| Stricturing (B2)                      | 25 (33.3)               |
| Penetrating (B3)                      | 45 (60.0)               |
| Perianal disease, n (%)               | 29 (38.7)               |
| Disease location, n (%)               |                         |
| Terminal ileum (L1)                   | 24 (32.0)               |
| Colon (L2)                            | 5 (6.7)                 |
| Ileocolon (L3)                        | 46 (61.3)               |
| Upper gastrointestinal disease (L4)   | 5 (6.7)                 |
| Endoscopic recurrence within 18 months, n (%) | 34 (45.3)          |
| Post-operative medication, n (%)      |                         |
| 5-ASA                                 | 4 (5.4)                 |
| Azathioprine                          | 39 (52.0)               |
| Mercaptopurine                        | 1 (1.3)                 |
| Methotrexate                          | 5 (6.7)                 |
| Thalidomide                           | 13 (17.3)               |
| Anti–TNF-α therapy                    | 13 (17.3)               |

CD, Crohn’s disease; IQR, interquartile range; 5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor.

### Figure 5. Expression of serum exosomal miR-144-3p in patients with Crohn’s disease after intestinal resection. The dotted line shows the cut-off value of 2.73. The majority of patients with expression of serum exosomal miR-144-3p more than the cut-off point of 2.73 were in endoscopic active stage (Rutgeerts score ≥12). sEV, small extracellular vesicle.

### Figure 6. Receiver-operating characteristic curves of serum exosomal miR-144-3p and clinical indices identifying endoscopic recurrence. Performances of serum exosomal miR-144-3p in detecting endoscopic recurrence compared with CRP and CDAI. CRP, C-reactive protein; CDAI, Crohn’s disease-activity index.
Circulating exosomal microRNA-144-3p in Crohn’s disease

from an originally non-complicating to a penetrating or stricturing behavior [40, 41]. Therefore, the determination of the complicated phenotype helps to identify high-risk patients and facilitates the administration of early intensive therapy. We found that circulating exosomal miR-144-3p levels were significantly higher in patients with penetrating diseases than in those with inflammatory and strictureing diseases (Figure 4). ROC analysis showed that a cut-off value of 3.11 identified endoscopically active disease with 70.2% sensitivity and 82.0% specificity, while a cut-off value of 8.92 yields a high specificity of 100% and a specificity of 33.3% for the penetrating phenotype. Therefore, extremely elevated expression of exosomal miR-144-3p may improve the detection of penetrating surgery. Severe complications of CD are indications for abdominal surgery. The present study showed that the expression of serum exosomal miR-144-3p significantly decreased after surgery; however, these levels were elevated in patients with endoscopic recurrence than in patients with endoscopic remission. Moreover, ROC analysis showed that exosomal miR-144-3p had a higher AUC, which can help to identify patients with endoscopic recurrence than the inflammatory marker CRP at 58.8% sensitivity and 92.7% specificity (AUC: 0.775 vs 0.639; P < 0.001). Furthermore, Wright et al. reported low performance of CRP and CDAI for detecting endoscopic recurrence, which was consistent with our findings [5].

The miR-144 family includes miR-144-3p and miR-144-5p, which are encoded in the 13q31.3 chromosome, and mediates erythroid homeostasis, tumorigenesis, and immune functions [42]. The miR-144 family target genes such as zonula occludens 1, anocytamin-1, and STAT family genes, as well as signaling pathways, such as the PI3K/AKT, NF-κB, Wnt, and JAK/STAT pathways [43–45]. Disanayake et al. reported that serum miR-144-3p is elevated during atopic dermatitis and plays a pro-inflammatory role by promoting the expression of human b-defensin-1 and SERPINB4 through activation of the NF-κB pathway [46]. miR-144 is aberrantly regulated in several types of cancers where it acts as a tumor suppressor or oncogene, depending on the tissue type [42]. Gaedcke et al. found that dysregulation of mucosa miR-144 is rectal-cancer-specific rather than colon cancer [47]. A series of studies have found that miR-144 could be a non-invasive biomarker in several cancers, such as fecal miR-144 in colorectal cancer, serum miR-144 in gastric cancer, and serum exosomal miR-144 in hepatocellular carcinoma [48–51]. However, exosomal miR-144 as a non-invasive marker of CD was examined for the first time in the current study. Recently, Rojas-Feria et al. reported that miR-144-3p was significantly induced in inflamed colonic mucosa compared with non-inflamed mucosa in patients with active CD [30]. However, the mechanism underlying the regulation of miR-144 in CD remains unclear and requires further investigation.

This study has some limitations. The microarray analysis for exosomal miRNA in our study included three healthy individuals and three CD patients. The small sample size may limit the discovery of novel miRNAs. Two miRNAs, namely miR-144-3p and miR-451a, showed significant difference (Supplementary Figure 1). MiR-451a was not upregulated in the colon tissue of CD patients and was not correlated with disease activity when validated in a larger sample size; therefore, only miR-144-3p was investigated in this study, which also limits the potential of using a panel of exosomal miRNAs to increase the predictive value. Further studies are required to investigate serum exosomal miRNAs in CD patients in a large sample size and explore a panel of exosomal miRNAs for CD monitoring. Moreover, although the upregulation of serum exosomal miR-144 indicates mucosal active disease, the miR-144 levels may not reflect the severity of the disease accurately due to their relatively weak correlation with CDAI (r = 0.343) and SES-CD (r = 0.547). Additionally, we did not evaluate fecal calprotectin, which has been shown to detect endoscopically active disease and post-operative recurrence. Further studies are needed to investigate the association between serum exosomal miR-144 and fecal calprotectin.

In conclusion, serum exosomal miR-144-3p levels may be valuable for monitoring CD. Extremely elevated exosomal miR-144-3p levels indicate the presence of penetrating complications. This approach is superior to using the inflammatory marker CRP for detecting early recurrence in CD patients after intestinal resection. Serum exosome miRNA is stable and easy to detect without invasive procedures and therefore may be useful in clinical practice. Further studies are needed to validate these findings in independent prospective cohorts.

**Supplementary Data**

**Supplementary data** is available at Gastroenterology Report online.

**Authors’ Contributions**

S.Z. and M.C. conceived of and supervised the study. Z.Z. supervised the study and provided necessary guidance. S.Z., M.C., and Z.Z. contributed equally to this work. P.C. conducted the experiments, performed patient follow-ups, and wrote the manuscript. S.H. analysed the data and revised the manuscript. Q.Y., K.C., Y.W., G.Z., and X.Z. collected serum samples and compiled clinical information. All authors have read and approved the final version of the manuscript.
Funding
This work was supported by the National Natural Science Foundation of China [grant numbers 81630018, 82070538, and 81870374], Guangdong Science and Technology Department [grant number 2017A030306021], and Guangzhou Science and Technology Department [grant number 202002030041].

Acknowledgements
We are grateful to the collaborators of the multidisciplinary team (MDT) of the First Affiliated Hospital of Sun Yat-sen University.

Conflict of Interest
None declared.

References
1. Torres J, Mehandru S, Colombel JF et al. Crohn’s disease. Lancet 2017;389:1741–55.
2. Cushing K, Higgins P. Management of Crohn disease: a review. JAMA 2021;325:69–80.
3. Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017;152:362–73.
4. Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Rev Gastroenterol Hepatol 2014;8:457–9.
5. Wright EK, Kamm MA, De Cruz P et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology 2015;148:938–47.
6. Annes e V, Daperno M, Rutter MD et al.; European Crohn’s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982–1018.
7. Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc 2020;91:733–45.
8. Brand EC, Elias SG, Minderhoud IM et al.; Dutch Initiative on Crohn and Colitis. Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn’s disease. Clin Gastroenterol Hepatol 2020;18:1704–18.
9. Dulai PS, Peyrin-Biroulet L, Danese S et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology 2019;157:1032–43.
10. Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367:6478.
11. Manier S, Liu CJ, Avet-Loiseau H et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 2017;129:2429–36.
12. O’Connell RM, Rao DS, Chaudhuri AA et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111–22.
13. Long H, Wang X, Chen Y et al. Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett 2018;428:90–103.
14. Alexander M, Hu R, Runtsch MC et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun 2015;6:7321.
15. Zhang H, Wang L, Li C et al. Exosome-induced regulation in inflammatory bowel disease. Front Immunol 2019;10:1464.
16. Desmond BJ, Dennett ER, Danielson KM. Circulating extracellular vesicle miRNA as diagnostic biomarkers in early colorectal cancer—a review. Cancers (Basel) 2019;12:52.
17. Tan D, Armitage J, Teo TH et al. Elevated levels of circulating exosome in COPD patients are associated with systemic inflammation. Respir Med 2017;132:261–4.
18. Kumar S, Vijayan M, Bhatti JS et al. MicroRNAs as peripheral biomarkers in aging and age-related diseases. Prog Mol Biol Transl Sci 2017;146:47–94.
19. Zheng M, Hou L, Ma Y et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer 2019;18:76.
20. Huang X, Yuan T, Liang M et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 2015;67:33–41.
21. Wu F, Guo NJ, Tian H et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2011;17:241–50.
22. Paraskevi A, Theodoropoulou G, Papakonstantinou I et al. Circulating microRNA in inflammatory bowel disease. J Crohns Colitis 2012;6:300–4.
23. Kriisansen GW, Yang Y, Mcqueen FM et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:520–30.
24. Chen P, Li Y, Li L et al. Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:733–43.
25. Oikonomopouloou A, Polytarchou C, Joshi S et al. Identification of circulating microRNA signatures in Crohn’s disease using the Nanostring nCounter Technology. Inflamm Bowel Dis 2016;22:2063–9.
26. Cortez MA, Bueso-Ramos C, Ferdin J et al. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467–77.
27. Schwarzenbach H, Nishida N, Calin GA et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11:145–56.
28. Min L, Zhu S, Chen L et al. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs. J Extracell Vesicles 2019;8:1643670.
29. Gomollón F, Dignass A, Annes e V, ECCO et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3–25.
30. Rojas-Feria M, Romero-Garcia T, Fernandez CJ et al. Modulation of faecal metagenome in Crohn’s disease: role of microRNAs as biomarkers. World J Gastroenterol 2018;24:5223–33.
31. Yang E, Panaccione N, Whitmire N et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease. Aliment Pharmacol Ther 2020;51:1031–8.
32. De Cruz P, Kamm MA, Hamilton AL et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients: a POCELER study analysis. Aliment Pharmacol Ther 2015;42:867–79.
33. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
34. Tang YT, Huang YY, Zheng L et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. Int J Mol Med 2017;40:834–44.
35. Ding M, Wang C, Lu X et al. Comparison of commercial exosome isolation kits for circulating exosomal microRNA profiling. Anal Bioanal Chem 2018;410:3805–14.
36. Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt 2014;34:502–8.
37. Leoni G, Neumann PA, Kamaly N et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest 2015;125:1215–27.
38. Zheng X, Chen F, Zhang Q et al. Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease. Protein Cell 2017;8:686–95.
39. Liu R, Tang A, Wang X et al. Inhibition of IncRNA NEAT1 suppresses the inflammatory response in IBD by modulating the intestinal epithelial barrier and by exosome-mediated polarization of macrophages. Int J Mol Med 2018;42:2903–13.
40. Dubinsky MC, Lin YC, Dutridge D et al.; Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360–7.
41. Hirten RP, Shah S, Sachar DB et al. The management of intestinal penetrating Crohn’s disease. Inflamm Bowel Dis 2018;24:752–65.
42. Kooshkaki O, Rezaei Z, Rahmati M et al. MiR-144: a new possible therapeutic target and diagnostic/prognostic tool in cancers. Int J Mol Sci 2020;21:2578.
43. Liu J, Xue H, Zhang J et al. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res 2015;34:35.
44. Guo Y, Ying L, Tian Y et al. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013;280:4531–8.
45. Jiang Y, Cai Y, Shao W et al. MicroRNA144 suppresses aggressive phenotypes of tumor cells by targeting ANO1 in colorectal cancer. Oncol Rep 2019;41:2361–70.
46. Dissanayake E, Inoue Y, Ochiai S et al. Hsa-mir-144-3p expression is increased in umbilical cord serum of infants with atopic dermatitis. J Allergy Clin Immunol 2019;143:447–50.
47. Gaedcke J, Grade M, Camps J et al. The rectal cancer microRNAome–microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012;18:4919–30.
48. Choi HH, Cho YS, Choi JH et al. Stool-based miR-92a and miR-144 as noninvasive biomarkers for colorectal cancer screening. Oncology 2019;97:173–9.
49. Kalimutho M, Del VBG, Di Cecilia S et al. Differential expression of miR-144 as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011;46:1391–402.
50. Liu S, Suo J, Wang C et al. Prognostic significance of low miR-144 expression in gastric cancer. Cancer Biomark 2017;20:547–52.
51. Pu C, Huang H, Wang Z et al. Extracellular vesicle-associated mir-21 and mir-144 are markedly elevated in serum of patients with hepatocellular carcinoma. Front Physiol 2018;9:930.